Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dutasteride

FDA-approved product (capsule, oral), marketed as Avodart, Dutasteride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dutasteride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia
  • Prostate adenocarcinoma
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Testosterone-5-alpha reductase inhibitors
FDA pharmacologic class
5-alpha Reductase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dutasteride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dutasteride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Impact of Long-term Dutasteride Use on Perioperative Outcomes of HoLEP

    NCT07417449 · start 2026-04-01

    Registered record
    Registry ID
    NCT07417449
    Conditions
    Prostatic Hyperplasia, Benign
    Interventions
    Dutasteride; Holmium Laser Enucleation of the Prostate (HoLEP)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2026-04-01
    Completion
    2027-04-01
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia, Benign
    InterventionDutasteride; Holmium Laser Enucleation of the Prostate (HoLEP)
    PhaseNot recorded
    Registry statusRecruiting

  • Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)

    NCT07421804 · start 2026-04

    Registered record
    Registry ID
    NCT07421804
    Conditions
    Acne Vulgaris
    Interventions
    topical dutasteride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-04
    Completion
    2028-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    Interventiontopical dutasteride
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects

    NCT07444385 · start 2026-02-26

    Registered record
    Registry ID
    NCT07444385
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    AD-116, AD-1161
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-02-26
    Completion
    2026-05-08
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionAD-116, AD-1161
    PhasePhase 1
    Registry statusRecruiting

  • MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine)

    NCT06110377 · start 2023-10-30

    Registered record
    Registry ID
    NCT06110377
    Conditions
    Androgenic Alopecia
    Interventions
    MESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE); MMP (INJECTIONS WITH A TATTOO MACHINE)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-10-30
    Completion
    2025-04-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAndrogenic Alopecia
    InterventionMESOTHERAPY (INJECTIONS WITH SYRINGE AND NEEDLE); MMP (INJECTIONS WITH A TATTOO MACHINE)
    PhasePhase 4
    Registry statusUnknown

  • Effetivity of Dutasteride and Aloe Vera Extract Combination on Angiogenesis and Obstruction on Benign Prostatic Hyperplasia

    NCT07065682 · start 2023-07-01

    Registered record
    Registry ID
    NCT07065682
    Conditions
    BPH (Benign Prostatic Hyperplasia)
    Interventions
    Aloevera + dutasteride; Dutasteride (0.5mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-07-01
    Completion
    2027-12-01
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBPH (Benign Prostatic Hyperplasia)
    InterventionAloevera + dutasteride; Dutasteride (0.5mg)
    PhasePhase 1
    Registry statusRecruiting

  • Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH

    NCT04245566 · start 2021-09

    Registered record
    Registry ID
    NCT04245566
    Conditions
    Benign Prostatic Hyperplasia; Pharmacotherapy; Prostatic Artery Embolization; Minimally Invasive Treatment
    Interventions
    Prostatic Artery Embolization (PAE); Pharmacotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-09
    Completion
    2025-12
    Enrolment
    425

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia; Pharmacotherapy; Prostatic Artery Embolization; Minimally Invasive Treatment
    InterventionProstatic Artery Embolization (PAE); Pharmacotherapy
    PhasePhase 3
    Registry statusUnknown

  • Study of PCUR-101 in Combination With ADT in Patients With mCRPC

    NCT04677855 · start 2021-03-30

    Registered record
    Registry ID
    NCT04677855
    Conditions
    Prostate Cancer
    Interventions
    PCUR-101; Dutasteride 0.5 mg; Abiraterone and Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2021-03-30
    Completion
    2023-11-20
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionPCUR-101; Dutasteride 0.5 mg; Abiraterone and Prednisone
    PhasePhase 1
    Registry statusTerminated

  • To Evaluate the Pharmacokinetics and Safety of AD-208

    NCT04214808 · start 2020-01-03

    Registered record
    Registry ID
    NCT04214808
    Conditions
    Androgenetic Alopecia
    Interventions
    AD-208; Avodart Soft Capsule 0.5mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-03
    Completion
    2020-05-04
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAndrogenetic Alopecia
    InterventionAD-208; Avodart Soft Capsule 0.5mg
    PhasePhase 1
    Registry statusCompleted

  • Dutasteride Treatment for Reducing Heavy Drinking in AUD: Predictors of Efficacy

    NCT04098302 · start 2019-10-15

    Registered record
    Registry ID
    NCT04098302
    Conditions
    Alcohol Use Disorder
    Interventions
    Dutasteride Capsules; Placebo Capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2019-10-15
    Completion
    2024-06-28
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Use Disorder
    InterventionDutasteride Capsules; Placebo Capsules
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil

    NCT03240939 · start 2017-03-27

    Registered record
    Registry ID
    NCT03240939
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Dutasteride 0.5 mg; Tadalafil 5 mg; YY-201
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-03-27
    Completion
    2017-10-10
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionDutasteride 0.5 mg; Tadalafil 5 mg; YY-201
    PhasePhase 1
    Registry statusCompleted

  • Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia

    NCT02869971 · start 2016-08

    Registered record
    Registry ID
    NCT02869971
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Embosphere® (Prostatic Arteries Embolization); Drug therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-08
    Completion
    2022-03-25
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionEmbosphere® (Prostatic Arteries Embolization); Drug therapy
    PhasePhase 3
    Registry statusCompleted

  • Safety and Pharmacokinetic Characteristics of DKF-313

    NCT02352311 · start 2015-01

    Registered record
    Registry ID
    NCT02352311
    Conditions
    Benign Prostate Hyperplasia; Healthy
    Interventions
    DKF-313; AVODART; CIALIS
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-01
    Completion
    2015-06
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostate Hyperplasia; Healthy
    InterventionDKF-313; AVODART; CIALIS
    PhasePhase 1
    Registry statusCompleted

  • Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

    NCT02184585 · start 2014-07-10

    Registered record
    Registry ID
    NCT02184585
    Conditions
    Prostatic Hyperplasia
    Interventions
    Treatment sequence A; Treatment sequence B; Treatment sequence C
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-07-10
    Completion
    2015-02-23
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionTreatment sequence A; Treatment sequence B; Treatment sequence C
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State

    NCT02058576 · start 2014-02-11

    Registered record
    Registry ID
    NCT02058576
    Conditions
    Urologic Diseases
    Interventions
    Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg; Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02-11
    Completion
    2015-01-02
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrologic Diseases
    InterventionCommercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg; Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
    PhasePhase 1
    Registry statusCompleted

  • This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples

    NCT01957189 · start 2013-10-25

    Registered record
    Registry ID
    NCT01957189
    Conditions
    Prostatic Hyperplasia
    Interventions
    Dutasteride and Tamsulosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10-25
    Completion
    2014-01-22
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionDutasteride and Tamsulosin
    PhasePhase 1
    Registry statusCompleted